Journal article
Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder
PV Magalhães, OM Dean, AI Bush, DL Copolov, D Weisinger, GS Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk
Progress in Neuro Psychopharmacology and Biological Psychiatry | Published : 2012
Abstract
Objectives: Bipolar disorder (BD) is intricately associated with chronic clinical conditions. Medical comorbidity is not only more prevalent in mood disorders, but is associated with increased costs, cognitive impairment and, ultimately, premature mortality. Oxidative stress and inflammation may mediate part of this association. To further investigate the association between medical comorbidity status and clinical improvement with adjuvant N acetyl cysteine (NAC) in the context of a placebo-controlled trial. Methods: Placebo-controlled randomized clinical trial assessing the effect of NAC over 24. weeks. Symptomatic and functional outcomes were collected over the study period. Medical comorb..
View full abstractGrants
Funding Acknowledgements
[ "This trial was supported by a grant from the Stanley Medical Research Institute, as well as the Mental Health Research Institute of Victoria. Trial registration: Australian Clinical Trials Registry 12605000362695, www.actr.org.au.", "Dr. Magalhaes is supported by a split doctoral scholarship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.", "Prof. Malhi has served on a number of international and national pharmaceutical advisory boards, received funding for research and has been in receipt of honoraria for talks at sponsored meetings worldwide involving the following companies: Astra Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Organon, Pfizer, Ranbaxy, Servier and Wyeth.", "Prof. Berk has received research support from: Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier. He has been a speaker for Speaker: Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, Wyeth. He has been a consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier." ]